Lord, Abbett & Co
RLAY icon

Lord, Abbett & Co’s Relay Therapeutics RLAY Stock Holding History

Lord, Abbett & Co’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-227,392
Closed -$9.69M – 693
2020
Q3 		$9.69M Buy
+227,392
New +$8.67M 0.03% 478

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Lord, Abbett & Co's RLAY Position: Q4 2020 in Review

Lord, Abbett & Co sold out of Relay Therapeutics (RLAY) in Q4 2020, closing a stake of 227,392 shares — an estimated $9.69M sold.

Lord, Abbett & Co first reported a position in RLAY in Q3 2020 and held it in 1 quarter. The position peaked at $9.69M in Q3 2020. 115 funds tracked by Wall St. Rank hold RLAY as of Q4 2020.

  • Lord, Abbett & Co reported no remaining Relay Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Lord, Abbett & Co sold 227,392 Relay Therapeutics shares in Q4 2020, an estimated $9.69M.
  • Lord, Abbett & Co first reported a position in Relay Therapeutics in Q3 2020 and held it in 1 quarter.
  • Lord, Abbett & Co's Relay Therapeutics position peaked at $9.69M in Q3 2020.
  • 115 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2020.

Based on Lord, Abbett & Co's 13F filing for Q4 2020, filed 9 Feb 2021.